Tasly Pharmaceutical Group Co., Ltd.

He Sun

Xiaohui Ma

Xijun Yan

Naifeng Wu

Kaijing Yan

Yonghong Zhu

Yi He

Shunnan Zhang

Ting Li

Xiaolin Bai

Lei Li

Shuiping Zhou

Jing Wang

Yanyong Liu

Zhixin Guo

Lijun Fan

Weiwei Liu

Lanlan Zhang

Min Han

Xinxin Li

Changwen Li

Zhijuan Huang

Guoguang Zhu

Ruizhi Luo

Wangyi Zhou

Zhaohui Song

Libin Zhao

Yiqian Zhang

Jiawen Shi

Xiaoqing Li

Yanchuan Li

Jingjing Zhang

A pharmaceutical composition is prepared from the following raw materials (in parts by weight): silybin (8.75-60), phospholipid (15-65), a Pu'er tea extract (25-200), and vitamin E (6.25-40). The composition has the effect of treating non-alcoholic fatty liver diseases.

Pharmaceutical composition containing silybin and VE

Disclosed are a pharmaceutical composition and an application thereof. The pharmaceutical composition of the present invention comprises the following components in parts by weight: 2-20 parts of phenolic acids, 0.5-5 parts of flavonoids, 0.005-0.5 part of tanshinones, 5-20 parts of saponins, and 10-18 parts of volatile oils. The pharmaceutical composition has the functions of protecting against myocardial damage and treating heart failure.

Pharmaceutical composition and application thereof

Pharmaceutical composition containing silybin and ve

Disclosed is an application of substituted cinnamamide derivatives in the preparation of anti-anxiety medications, the substituted cinnammide derivatives are compounds having the structure of formula (I) or pharmaceutically acceptable salts thereof, wherein, Ris &#x2014;H, &#x2014;OH, &#x2014;F, &#x2014;Cl, &#x2014;Br, &#x2014;I, &#x2014;OCH, &#x2014;OCF, &#x2014;OCHF, &#x2014;OCHF, &#x2014;CF, &#x2014;CHF, &#x2014;CHF, &#x2014;CH, &#x2014;CHCH, &#x2014;CFCH, &#x2014;CN, &#x2014;NO, &#x2014;NHor &#x2014;COOR; Ris H, C-Clinear alkyl, C-Cbranched alkyl, C-Ccyclic alkyl, C-Chydroxyalkyl or a N-substituted piperazine-derived group; or Ris a group forming with adjacent Y a tetrahydropyrrolyl group, a piperidyl group or a cyclohexanimido group. 

Application of substituted cinnamamide derivatives in preparation of anti-anxiety medication

Disclosed is a pharmaceutical composition containing silibinin, which is prepared from the following bulk drugs by weight ratio: 8.75-60 parts of silibinin, 15-65 parts of phospholipid, and 25-200 parts of Pu'er tea extract. The drug has the function of treating non-alcoholic fatty liver.

Pharmaceutical composition containing silibinin

Disclosed are a pharmaceutical composition for treating non-alcoholic fatty liver and a method for preparing same. The composition is prepared from the following hulk drugs by weight ratio: 8.75-60 parts of silibinin, 15-65 parts of phospholipid, 25-200 parts of Pu'er tea extract, and 5-50 parts of radix puerariae extract.

Pharmaceutical composition containing silibinin and pueraria root extract

A pharmaceutical composition for treating non-alcoholic fatty liver diseases consists of a silybin-phospholipid complex preparation and Pu'er tea/tea product according to a weight ratio of 0.5-2.5:0.3-10, wherein the silybin-phospholipid complex capsule preparation and the Pu'er teat/tea product are separately packaged.

Pharmaceutical composition containing silybin

A pharmaceutical composition for treating non-alcoholic fatty liver diseases. The pharmaceutical composition is prepared from 8.75-60 parts by weight of silybin, 15-65 parts by weight of phospholipid, 25-150 parts by weight of a Pu'er tea extract, and 10.425-60 parts by weight of L-carnitine.

Pharmaceutical composition containing silybin and L-carnitine

A pharmaceutical composition. The pharmaceutical composition is prepared from the following raw materials in parts by weight: 8.75-60 parts of silybin, 15-65 parts of phospholipid, 25-200 parts of a Pu'er tea extract, 6.25-40 parts of vitamin E, and 8.3-60 parts of L-carnitine. The composition can be used for treating non-alcoholic fatty liver diseases.

Pharmaceutical composition containing silybin, VE and L-carnitine

A capsule of compound danshen dripping pills are disclosed. The color of the capsule's shell is orange, yellow, green or blue and all of these colors are in the wavelength range of 446-620 nm.

Capsule of compound danshen dripping pills

Provided is the use of acomposition in preparing drugs for secondary prevention of coronary heart disease, and particularly the use of thecomposition in preparing drugs for secondary prevention of stable angina type coronary heart disease and the reduction of serious vascular events.

[object Object]

Growing community of inventors

Tianjin, China

He Sun